LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel

NCT02182622 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Docetaxel
DRUG: Prednisone
DRUG: LDE225

Sponsor

Martin Gutierrez

Collaborators

[object Object]